Expression and significance of extracellular matrix and cell adhesion molecule in bronchiolo-alveolar carcinoma

SONG Bo * E-KU Min E-NIE Hualing E-ZHENG Renshu E-BAI Jie E-TANG Jianmu. * Department of Pathology E-Italian Medical University E-Italian E-Luozong 116023 E-P. R. China

Abstract Objective To study the expression features and significance of extracellular matrix ECM and adhesion molecule A-CAM in the three subtypes of the bronchiolo-alveolar carcinoma and conventional pulmonary adenocarcinoma. Methods Using immunohistochemical LSAB technique, the distribution and expression of ECM and A-CAM were examined in 50 cases of BAC including 14 mucinous, 14 nonmucinous and 14 sclerosing BAC and 6 of CPA. Results LNE Coll IV and FN in the basement membrane were stained as uninterrupted narrow line in the mucinous BAC and the pulmonary parenchyma adjacent to the carcinoma. In nonmucinous BAC ECM showed as irregular tram-track like double layers. The peripheral areas of the sclerosing BAC was virtually identical in staining pattern to the nonmucinous BAC and the central areas which showed disrupted or absent in the basement membrane surrounding the glands embedded in the fibrous stroma similar to that of CPA. The frequency of A-CAM expression in BAC and CPA was 60% 30/50 and 83% 5/6 respectively with no significant correlation found. The percentage of A-CAM in three BAC subtypes was 43% 6/14, 12/22 and 86% 12/14 which appeared as increased tendency. There was a significant difference between the mucinous and sclerosing BAC P < 0.05 while the sclerosing BAC was close to CPA. Conclusion On the basis of the distribution and expression of ECM and A-CAM the BAC should be taken as a subtype of CPA. The mucinous BAC may be a real BAC. Perhaps there is some differentiation correlation among three subtypes of BAC and CPA.

Key words Extracellular matrix Cell adhesion molecule Bronchiolo-alveolar carcinoma Conventional pulmonary adenocarcinoma
2.1 ECM 

2.2 A-CAM 

Figure 1: Immunohistochemical staining of Coll IV in the mucinous bronchoalveolar carcinoma. 

Figure 2: Immunohistochemical staining of LN in the nonmucinous BAC was showed as uninterrupted tran-track like double layers in the basement membrane.
Fig 3 Immuno-histochemical staining of FN in the central areas of sclerosing
BAC was disrupted or absent in the basement membrane  LSAB method
× 100

Fig 4 Immuno-histochemical staining of A-CAM in the nonmucinous BAC was
distinctly positive in the cytoplasm  LSAB method × 200

8 Falk RF, Pickle L, Welmouth EM et al. Epidemiology of bronchioloalve-
两种以上药物交替注射治疗肺癌胸腔积液

1. **UOCE**
2. **IAAV**
3. **AUCA**

<table>
<thead>
<tr>
<th>Table 1</th>
<th>The doses and administration times of chemotherapy drugs given to the patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug</td>
<td>DDP</td>
</tr>
<tr>
<td>Dose (mg)</td>
<td>30 - 60</td>
</tr>
<tr>
<td>No. of times</td>
<td>61</td>
</tr>
</tbody>
</table>

1. **AU**
2. **2+**
3. **AUAOE**
4. **24**
5. **66.7**
6. **LEO**
7. **PRR**
8. **88.9**
9. **EIA**
10. **EIA**
11. **EIA**
12. **EIA**
13. **EIA**
14. **EIA**
15. **EIA**
16. **EIA**
17. **EIA**
18. **EIA**
19. **EIA**
20. **EIA**
21. **EIA**
22. **EIA**
23. **EIA**
24. **EIA**
25. **EIA**
26. **EIA**
27. **EIA**
28. **EIA**
29. **EIA**
30. **EIA**
31. **EIA**
32. **EIA**
33. **EIA**
34. **EIA**
35. **EIA**
36. **EIA**
37. **EIA**
38. **EIA**
39. **EIA**
40. **EIA**
41. **EIA**
42. **EIA**
43. **EIA**
44. **EIA**
45. **EIA**
46. **EIA**
47. **EIA**
48. **EIA**
49. **EIA**
50. **EIA**
51. **EIA**
52. **EIA**
53. **EIA**
54. **EIA**
55. **EIA**
56. **EIA**
57. **EIA**
58. **EIA**
59. **EIA**
60. **EIA**
61. **EIA**
62. **EIA**
63. **EIA**
64. **EIA**
65. **EIA**
66. **EIA**
67. **EIA**
68. **EIA**
69. **EIA**
70. **EIA**
71. **EIA**
72. **EIA**
73. **EIA**
74. **EIA**
75. **EIA**
76. **EIA**
77. **EIA**
78. **EIA**
79. **EIA**
80. **EIA**
81. **EIA**
82. **EIA**
83. **EIA**
84. **EIA**
85. **EIA**
86. **EIA**
87. **EIA**
88. **EIA**
89. **EIA**
90. **EIA**
91. **EIA**
92. **EIA**
93. **EIA**
94. **EIA**
95. **EIA**
96. **EIA**
97. **EIA**
98. **EIA**
99. **EIA**
100. **EIA**

2. **7+**